Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton

Ilgen Mender, Serif Senturk, Nuriman Ozgunes, K. Can Akcali, Dimitris Kletsas, Sergei Gryaznov, Alp Can, Jerry W. Shay, Z. Gunnur Dikmen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.

Original languageEnglish (US)
Pages (from-to)1709-1715
Number of pages7
JournalInternational Journal of Oncology
Volume42
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Telomerase
Cytoskeleton
Telomere
Neoplasms
Maintenance
Clinical Trials
Cell Line
Ribonucleoproteins
Intermediate Filaments
RNA-Directed DNA Polymerase
Matrix Metalloproteinase 2
G1 Phase
Cadherins
Tubulin
Actin Cytoskeleton
Heterografts
Cell Adhesion
Non-Small Cell Lung Carcinoma
Oligonucleotides
Lung Neoplasms

Keywords

  • Cell adhesion
  • E-cadherin
  • GRN163L
  • Matrix metalloproteinase-2
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mender, I., Senturk, S., Ozgunes, N., Can Akcali, K., Kletsas, D., Gryaznov, S., ... Dikmen, Z. G. (2013). Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton. International Journal of Oncology, 42(5), 1709-1715. https://doi.org/10.3892/ijo.2013.1865

Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton. / Mender, Ilgen; Senturk, Serif; Ozgunes, Nuriman; Can Akcali, K.; Kletsas, Dimitris; Gryaznov, Sergei; Can, Alp; Shay, Jerry W.; Dikmen, Z. Gunnur.

In: International Journal of Oncology, Vol. 42, No. 5, 05.2013, p. 1709-1715.

Research output: Contribution to journalArticle

Mender, I, Senturk, S, Ozgunes, N, Can Akcali, K, Kletsas, D, Gryaznov, S, Can, A, Shay, JW & Dikmen, ZG 2013, 'Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton', International Journal of Oncology, vol. 42, no. 5, pp. 1709-1715. https://doi.org/10.3892/ijo.2013.1865
Mender I, Senturk S, Ozgunes N, Can Akcali K, Kletsas D, Gryaznov S et al. Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton. International Journal of Oncology. 2013 May;42(5):1709-1715. https://doi.org/10.3892/ijo.2013.1865
Mender, Ilgen ; Senturk, Serif ; Ozgunes, Nuriman ; Can Akcali, K. ; Kletsas, Dimitris ; Gryaznov, Sergei ; Can, Alp ; Shay, Jerry W. ; Dikmen, Z. Gunnur. / Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton. In: International Journal of Oncology. 2013 ; Vol. 42, No. 5. pp. 1709-1715.
@article{af7d572fec3f4cfb9c73dc8092125bfb,
title = "Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton",
abstract = "Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90{\%} of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.",
keywords = "Cell adhesion, E-cadherin, GRN163L, Matrix metalloproteinase-2, Non-small cell lung cancer",
author = "Ilgen Mender and Serif Senturk and Nuriman Ozgunes and {Can Akcali}, K. and Dimitris Kletsas and Sergei Gryaznov and Alp Can and Shay, {Jerry W.} and Dikmen, {Z. Gunnur}",
year = "2013",
month = "5",
doi = "10.3892/ijo.2013.1865",
language = "English (US)",
volume = "42",
pages = "1709--1715",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton

AU - Mender, Ilgen

AU - Senturk, Serif

AU - Ozgunes, Nuriman

AU - Can Akcali, K.

AU - Kletsas, Dimitris

AU - Gryaznov, Sergei

AU - Can, Alp

AU - Shay, Jerry W.

AU - Dikmen, Z. Gunnur

PY - 2013/5

Y1 - 2013/5

N2 - Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.

AB - Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.

KW - Cell adhesion

KW - E-cadherin

KW - GRN163L

KW - Matrix metalloproteinase-2

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84875984655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875984655&partnerID=8YFLogxK

U2 - 10.3892/ijo.2013.1865

DO - 10.3892/ijo.2013.1865

M3 - Article

C2 - 23545855

AN - SCOPUS:84875984655

VL - 42

SP - 1709

EP - 1715

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -